Developer docs
API playgroundTry for free, no card

Search company profiles

The DeGregorio Family Foundation

Full company profile

uuid003bj9s

Namestring
The DeGregorio Family Foundation
Legal namestring
DeGregorio Family Foundation Inc.
Websiteurl
degregorio.org
Company typeenum
Private
Founded yearint
2006
Descriptiontext

The DeGregorio Family Foundation is a 501(c)(3) nonprofit charitable organization founded in 2006 by Lynn DeGregorio after multiple family members died from Hereditary Diffuse Gastric Cancer. It is the only public foundation in the United States solely dedicated to funding peer-reviewed scientific research in both gastric and esophageal cancers (gastroesophageal cancers). The foundation does not develop technology products; its core activity is grant-making to academic researchers and physician-scientists at institutions including Memorial Sloan Kettering, Dana-Farber, MD Anderson, Weill Cornell Medicine, Columbia, Mayo Clinic, University of Pennsylvania, Fred Hutchinson Cancer Center, MD Anderson and others.

Over a 20-year operating history (2006–2026), the foundation has awarded approximately $10 million across 38 research grants and documented $56 million+ in follow-on funding from the NIH, Department of Defense, the Starr Foundation, and other institutional sources — a 1:12 leverage ratio. Grant selection is managed by an external Scientific Advisory Board chaired by Dr. Manish Shah. The operating principle commits 100% of donated funds directly to research.

Revenue is generated entirely through tax-deductible donations, sourced across multiple channels: an annual gala held at the New York Yacht Club (minimum $275 ticket, plus patron and table sponsorship tiers); the “Run With Us” program fielding guaranteed-entry fundraising teams in the TCS New York City Marathon ($3,500 commitment per runner) and United Airlines NYC Half ($1,500); direct online donations via degregorio.org; legacy and estate gifts; and co-branded grants underwritten with co-funders including the Torrey Coast Foundation (via GEMINI, with grants up to $1 million), the Price Family Foundation, and the Esophageal Cancer Awareness Association. The foundation operates from New York, NY (HQ) and Pleasantville, NY (mailing), with 1–10 employees and no parent company, equity backing, or disclosed institutional investors.

Short descriptiontext

The DeGregorio Family Foundation is a 501(c)(3) nonprofit founded in 2006 that funds peer-reviewed gastric and esophageal cancer research grants at academic and cancer-center institutions in the U.S. and abroad, supported by an annual gala, marathon fundraising, online donations, and co-funders.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPleasantville, United States
HQ citystring
Pleasantville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer research grants, nonprofit fundraising, gastroesophageal cancer research, charitable foundation grants, medical research funding
Industry2 codes
1Health & Medical Research Grantmaking Foundations
CodeBPAGAKALPrimaryYes
2Research & Science Grantmaking Foundations
CodeBPAGAKAIPrimaryNo
NAICS code2 codes
  • Grantmaking Foundations813211
  • Voluntary Health Organizations813212
SIC code1 code
  • Services-Social Services8300
Product category
Nonprofit Cancer Research Foundation
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Donations and Contributions
TypeGrants Donations
Description

The foundation raises funds through individual donations (online portal), annual gala ticket sales and contributions, event-based fundraising (marathon runners commit to raise minimum amounts), and legacy/estate gifts. All funds are designated as 501(c)(3) charitable contributions and go entirely to research grants.

degregorio.org
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Operations, Marketing or Sales, Personnel, Others
Pricing details4 tiers
1Annual Gala Admission ticket
ModelOne time/ perpetual licenseBilling cadenceAnnual
Notes

Minimum ticket price $275 per person at the DeGregorio Family Foundation Annual Gala (held at the New York Yacht Club). Patron levels and table sponsorships available at higher contribution levels.

degregorio.org
2TCS New York City Marathon – Team DeGregorio fundraising commitment
ModelOutcome Based/ PerformanceBilling cadencePay-as-you-go
Notes

Each runner must raise $3,500 by October 31, 2026. Guaranteed race entry in exchange for fundraising commitment.

degregorio.org
3United Airlines NYC Half Marathon – Team DeGregorio fundraising commitment
ModelOutcome Based/ PerformanceBilling cadencePay-as-you-go
Notes

Each runner must raise $1,500 by March 15, 2026. Guaranteed race entry in exchange for fundraising commitment.

degregorio.org
4Online donations
ModelOtherBilling cadencePay-as-you-go
Notes

Donations accepted at https://degregorio.org/donate; legacy/estate gifts arranged by contacting [email protected].

degregorio.org
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

The DeGregorio Family Foundation is a 501(c)(3) nonprofit foundation that raises donations from individuals, gala attendees, marathon fundraisers, and planned/legacy givers, and awards peer-reviewed research grants to academic researchers and physician-scientists studying gastric and esophageal cancers. It also convenes a Scientific Advisory Board that selects grant recipients and operates fundraising events including an annual gala and running programs to support its grant-making mission.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • For every $1 donated, $12 is generated in follow-on funding from NIH, Department of Defense, Starr Foundation, and other institutional sources.
+2 more records
Product overview1 text field

The DeGregorio Family Foundation is a 501(c)(3) nonprofit charitable organization focused exclusively on funding innovative research to cure gastric and esophageal cancers (gastroesophageal cancers). Founded in 2006 after multiple family members died from Hereditary Diffuse Gastric Cancer, the foundation awards research grants to academic researchers at institutions worldwide, supports early-stage projects to foster clinical advancements, and hosts fundraising events including annual galas and running events. The foundation has awarded nearly $10 million through 38 grants over 20 years, with a model where 100% of funds go directly to research, and has generated over $56 million in follow-on funding for completed grants. The organization does not offer commercial products or technology services.

Product and service5 records
1Research Grant Program
CategoryResearch grant funding
Description

Peer-reviewed research grants awarded to academic researchers and physician-scientists at cancer centers and universities for gastric and esophageal cancer research. Funds early-stage, high-impact projects intended to attract follow-on funding from sources such as the NIH and Department of Defense.

2Annual Gala
CategoryFundraising event
Description

Ticketed annual fundraising gala held at the New York Yacht Club featuring patron levels and table sponsorships; minimum ticket price $275 per person. Combines fundraising with community building among donors, board members, and researchers.

3Run With Us — TCS New York City Marathon Team
CategoryFundraising event
Description

Marathon fundraising program offering guaranteed race entry into the TCS New York City Marathon to runners who commit to raise a minimum of $3,500 for the foundation by October 31, 2026.

4Run With Us — United Airlines NYC Half Team
CategoryFundraising event
Description

Half-marathon fundraising program offering guaranteed race entry into the United Airlines NYC Half Marathon to runners who commit to raise a minimum of $1,500 for the foundation by March 15, 2026.

5Legacy Giving / Planned Giving Program
CategoryPlanned giving
Description

Planned giving program for high-net-worth donors that accepts bequests in wills, life insurance policy donations, retirement plan beneficiary designations, and charitable remainder trusts to support the foundation's research mission.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeOthers
Description

GuideStar Platinum Seal认证 (2026) recognizes DFF's nonprofit transparency, operational disclosure, and financial accountability. The Platinum seal is the highest level of GuideStar's Candid platform.

Strategic tierMinorTypeOthers
Description

Charity Navigator 4-star rating (2026) for DFF (EIN 83-0465493), indicating strong financial health and accountability. This third-party rating enhances donor trust and confidence.

3GEMINI (Gastro Esophageal Investigator Network Initiative)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

GEMINI is an initiative of the Torrey Coast Foundation that partners with DFF to award collaborative research grants in gastroesophageal cancer. GEMINI brings together a network of investigators and co-funds grants of up to $1 million, including grants to Dr. Joseph Caster at University of Iowa, Dr. Saar Gill at UPenn, and Dr. Eric Smith at Dana-Farber.

degregorio.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Large pancreatic cancer research foundation operating a similar grantmaking + co-funding model with a distinguished Scientific Advisory Board, marathon programs, and notable leverage of donor dollars into follow-on NIH funding. Direct architectural peer in disease-specific cancer research philanthropy.

TypeDirect peer
Description

Patient-and-research-focused nonprofit serving the esophageal cancer community, supporting research grants and family education. Comparable to DFF in disease subset (esophageal cancer), small-team operating model, and event-based fundraising.

TypeBroad incumbent
Description

The largest U.S. nonprofit funder of cancer research and patient support, funding gastroesophageal cancer among many other cancer types. Compares as a broad incumbent with overlapping patient and research missions but vastly larger scale, scope, and donor base.

TypeBroad incumbent
Description

Nationally recognized cancer research grantmaking organization funding 'translational' and 'bench-to-bedside' oncology research across many cancer types. Broader incumbent operating a similar grant-and-SAB model as DFF, but at much larger scale and across all cancer types.

TypeBroad incumbent
Description

Nonprofit funding cancer prevention and early-detection research across multiple cancer types. Relevant peer because DFF explicitly funds early-diagnosis research (e.g., Barrett's esophagus screening, GERD-related esophageal cancer), but Prevent Cancer operates at significantly broader scope and scale.

TypeBroad incumbent
Description

Established cancer research grantmaker funding early-career investigators across solid tumors including GI cancers. Comparable peer in research-grantmaking-with-SAB-curation model, but operating across many cancer types at meaningfully larger scale.

TypeDirect peer
Description

Nonprofit focused on raising awareness and funding research for esophageal and gastric cancers through community events (primarily running-based). Highly comparable to DFF in disease focus, fundraising channel mix (marathons/gala-style events), and grant-funded research model.

TypeBroad incumbent
Description

Nonprofit funding immunotherapy research across cancers, including CAR-T/CAR-NK/CAR-macrophage approaches that DFF is also funding (Saar Gill, Katy Rezvani, Eric Smith grants). Comparable peer in funding-immunotherapy angle of gastroesophageal cancer but operates across all oncology.

TypeRegional player
Description

Childhood-cancer-focused research foundation using an event-led, donor-driven grantmaking model similar to DFF. Compares on operational archetype (small foundation, named research grants, marathon/community events) rather than disease focus.

TypeDirect peer
Description

Nonprofit foundation raising funds to support hereditary diffuse gastric cancer (HDGC) and gastric cancer research, with an emphasis on CDH1 mutation awareness. Most direct peer to DFF given overlapping focus on HDGC research and the gastroesophageal cancer patient/family community.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles27 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

The DeGregorio Family Foundation

Nonprofit Cancer Research Foundationdegregorio.org

The DeGregorio Family Foundation is a 501(c)(3) nonprofit founded in 2006 that funds peer-reviewed gastric and esophageal cancer research grants at academic and cancer-center institutions in the U.S. and abroad, supported by an annual gala, marathon fundraising, online donations, and co-funders.

What The DeGregorio Family Foundation does

The DeGregorio Family Foundation is a 501(c)(3) nonprofit charitable organization founded in 2006 by Lynn DeGregorio after multiple family members died from Hereditary Diffuse Gastric Cancer. It is the only public foundation in the United States solely dedicated to funding peer-reviewed scientific research in both gastric and esophageal cancers (gastroesophageal cancers). The foundation does not develop technology products; its core activity is grant-making to academic researchers and physician-scientists at institutions including Memorial Sloan Kettering, Dana-Farber, MD Anderson, Weill Cornell Medicine, Columbia, Mayo Clinic, University of Pennsylvania, Fred Hutchinson Cancer Center, MD Anderson and others.

Over a 20-year operating history (2006–2026), the foundation has awarded approximately $10 million across 38 research grants and documented $56 million+ in follow-on funding from the NIH, Department of Defense, the Starr Foundation, and other institutional sources — a 1:12 leverage ratio. Grant selection is managed by an external Scientific Advisory Board chaired by Dr. Manish Shah. The operating principle commits 100% of donated funds directly to research.

Revenue is generated entirely through tax-deductible donations, sourced across multiple channels: an annual gala held at the New York Yacht Club (minimum $275 ticket, plus patron and table sponsorship tiers); the “Run With Us” program fielding guaranteed-entry fundraising teams in the TCS New York City Marathon ($3,500 commitment per runner) and United Airlines NYC Half ($1,500); direct online donations via degregorio.org; legacy and estate gifts; and co-branded grants underwritten with co-funders including the Torrey Coast Foundation (via GEMINI, with grants up to $1 million), the Price Family Foundation, and the Esophageal Cancer Awareness Association. The foundation operates from New York, NY (HQ) and Pleasantville, NY (mailing), with 1–10 employees and no parent company, equity backing, or disclosed institutional investors.

The DeGregorio Family Foundation firmographics

Firmographics
Name
The DeGregorio Family Foundation
Legal name
DeGregorio Family Foundation Inc.
Website
https://degregorio.org
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
The DeGregorio Family Foundation is a 501(c)(3) nonprofit founded in 2006 that funds peer-reviewed gastric and esophageal cancer research grants at academic and cancer-center institutions in the U.S. and abroad, supported by an annual gala, marathon fundraising, online donations, and co-funders.
Ownership category
akta.pro rank

The DeGregorio Family Foundation industry classification

Industry
Product category
Nonprofit Cancer Research Foundation
NAICS
Grantmaking Foundations (813211), Voluntary Health Organizations (813212)
SIC
Services-Social Services (8300)
akta.pro primary industry
Health & Medical Research Grantmaking Foundations (BPAGAKAL)
akta.pro secondary industry
Research & Science Grantmaking Foundations (BPAGAKAI)

Keywords

  • Cancer research grants
  • Nonprofit fundraising
  • Gastroesophageal cancer research
  • Charitable foundation grants
  • Medical research funding

Where The DeGregorio Family Foundation is headquartered

Location

Headquarters

HQ city
Pleasantville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

The DeGregorio Family Foundation business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Operations, Marketing or Sales, Personnel, Others

Revenue model

  1. Donations and Contributions: The foundation raises funds through individual donations (online portal), annual gala ticket sales and contributions, event-based fundraising (marathon runners commit to raise minimum amounts), and legacy/estate gifts. All funds are designated as 501(c)(3) charitable contributions and go entirely to research grants.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseAnnualAnnual Gala Admission ticket
Outcome Based/ PerformancePay-as-you-goTCS New York City Marathon – Team DeGregorio fundraising commitment
Outcome Based/ PerformancePay-as-you-goUnited Airlines NYC Half Marathon – Team DeGregorio fundraising commitment
OtherPay-as-you-goOnline donations

Go-to-market motion2 records

Distribution channels5 records

Marketing channels10 records

The DeGregorio Family Foundation product offering

Product offering

Core offering

The DeGregorio Family Foundation is a 501(c)(3) nonprofit foundation that raises donations from individuals, gala attendees, marathon fundraisers, and planned/legacy givers, and awards peer-reviewed research grants to academic researchers and physician-scientists studying gastric and esophageal cancers. It also convenes a Scientific Advisory Board that selects grant recipients and operates fundraising events including an annual gala and running programs to support its grant-making mission.

Product overview

The DeGregorio Family Foundation is a 501(c)(3) nonprofit charitable organization focused exclusively on funding innovative research to cure gastric and esophageal cancers (gastroesophageal cancers). Founded in 2006 after multiple family members died from Hereditary Diffuse Gastric Cancer, the foundation awards research grants to academic researchers at institutions worldwide, supports early-stage projects to foster clinical advancements, and hosts fundraising events including annual galas and running events. The foundation has awarded nearly $10 million through 38 grants over 20 years, with a model where 100% of funds go directly to research, and has generated over $56 million in follow-on funding for completed grants. The organization does not offer commercial products or technology services.

Differentiator

Problem solved

Functional benefit

Products and services

  • Research Grant Program Peer-reviewed research grants awarded to academic researchers and physician-scientists at cancer centers and universities for gastric and esophageal cancer research. Funds early-stage, high-impact projects intended to attract follow-on funding from sources such as the NIH and Department of Defense.
  • Annual Gala Ticketed annual fundraising gala held at the New York Yacht Club featuring patron levels and table sponsorships; minimum ticket price $275 per person. Combines fundraising with community building among donors, board members, and researchers.
  • Run With Us — TCS New York City Marathon Team Marathon fundraising program offering guaranteed race entry into the TCS New York City Marathon to runners who commit to raise a minimum of $3,500 for the foundation by October 31, 2026.
  • Run With Us — United Airlines NYC Half Team Half-marathon fundraising program offering guaranteed race entry into the United Airlines NYC Half Marathon to runners who commit to raise a minimum of $1,500 for the foundation by March 15, 2026.
  • Legacy Giving / Planned Giving Program Planned giving program for high-net-worth donors that accepts bequests in wills, life insurance policy donations, retirement plan beneficiary designations, and charitable remainder trusts to support the foundation's research mission.

Quantifiable outcome

  • For every $1 donated, $12 is generated in follow-on funding from NIH, Department of Defense, Starr Foundation, and other institutional sources.
  • +2 more outcomes

Companies that use The DeGregorio Family Foundation

Customer profile

Segments2 records

Ideal customer profiles2 records

The DeGregorio Family Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

The DeGregorio Family Foundation partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • GuideStar (Candid)minorOthersGuideStar Platinum Seal认证 (2026) recognizes DFF's nonprofit transparency, operational disclosure, and financial accountability. The Platinum seal is the highest level of GuideStar's Candid platform.
  • Charity NavigatorminorOthersCharity Navigator 4-star rating (2026) for DFF (EIN 83-0465493), indicating strong financial health and accountability. This third-party rating enhances donor trust and confidence.
  • GEMINI (Gastro Esophageal Investigator Network Initiative)coreStrategic or Co-development PartnerGEMINI is an initiative of the Torrey Coast Foundation that partners with DFF to award collaborative research grants in gastroesophageal cancer. GEMINI brings together a network of investigators and co-funds grants of up to $1 million, including grants to Dr. Joseph Caster at University of Iowa, Dr. Saar Gill at UPenn, and Dr. Eric Smith at Dana-Farber.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

The DeGregorio Family Foundation competitors and assessment

Company assessment

Direct peers

  • Lustgarten Foundation: Large pancreatic cancer research foundation operating a similar grantmaking + co-funding model with a distinguished Scientific Advisory Board, marathon programs, and notable leverage of donor dollars into follow-on NIH funding. Direct architectural peer in disease-specific cancer research philanthropy.
  • Esophageal Cancer Education Foundation (ECEF): Patient-and-research-focused nonprofit serving the esophageal cancer community, supporting research grants and family education. Comparable to DFF in disease subset (esophageal cancer), small-team operating model, and event-based fundraising.
  • SALGI Foundation: Nonprofit focused on raising awareness and funding research for esophageal and gastric cancers through community events (primarily running-based). Highly comparable to DFF in disease focus, fundraising channel mix (marathons/gala-style events), and grant-funded research model.
  • No Stomach for Cancer: Nonprofit foundation raising funds to support hereditary diffuse gastric cancer (HDGC) and gastric cancer research, with an emphasis on CDH1 mutation awareness. Most direct peer to DFF given overlapping focus on HDGC research and the gastroesophageal cancer patient/family community.

Broad incumbents

  • American Cancer Society: The largest U.S. nonprofit funder of cancer research and patient support, funding gastroesophageal cancer among many other cancer types. Compares as a broad incumbent with overlapping patient and research missions but vastly larger scale, scope, and donor base.
  • V Foundation for Cancer Research: Nationally recognized cancer research grantmaking organization funding 'translational' and 'bench-to-bedside' oncology research across many cancer types. Broader incumbent operating a similar grant-and-SAB model as DFF, but at much larger scale and across all cancer types.
  • Prevent Cancer Foundation: Nonprofit funding cancer prevention and early-detection research across multiple cancer types. Relevant peer because DFF explicitly funds early-diagnosis research (e.g., Barrett's esophagus screening, GERD-related esophageal cancer), but Prevent Cancer operates at significantly broader scope and scale.
  • Damon Runyon Cancer Research Foundation: Established cancer research grantmaker funding early-career investigators across solid tumors including GI cancers. Comparable peer in research-grantmaking-with-SAB-curation model, but operating across many cancer types at meaningfully larger scale.
  • Cancer Research Institute: Nonprofit funding immunotherapy research across cancers, including CAR-T/CAR-NK/CAR-macrophage approaches that DFF is also funding (Saar Gill, Katy Rezvani, Eric Smith grants). Comparable peer in funding-immunotherapy angle of gastroesophageal cancer but operates across all oncology.

Regional players

  • Rally Foundation for Childhood Cancers: Childhood-cancer-focused research foundation using an event-led, donor-driven grantmaking model similar to DFF. Compares on operational archetype (small foundation, named research grants, marathon/community events) rather than disease focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

The DeGregorio Family Foundation social profiles

Digital presence

The DeGregorio Family Foundation compliance and trust

Trust signal

Compliance1 record

The DeGregorio Family Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

The DeGregorio Family Foundation leadership team

Management profile

Number of profiles

Profiles27 records

The DeGregorio Family Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

The DeGregorio Family Foundation M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The DeGregorio Family Foundation

What does The DeGregorio Family Foundation do?

The DeGregorio Family Foundation is a 501(c)(3) nonprofit foundation that raises donations from individuals, gala attendees, marathon fundraisers, and planned/legacy givers, and awards peer-reviewed research grants to academic researchers and physician-scientists studying gastric and esophageal cancers. It also convenes a Scientific Advisory Board that selects grant recipients and operates fundraising events including an annual gala and running programs to support its grant-making mission.

Is The DeGregorio Family Foundation a public or private company?

The DeGregorio Family Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was The DeGregorio Family Foundation founded?

The DeGregorio Family Foundation was founded in 2006. It employs 1 to 10 people.

Where is The DeGregorio Family Foundation based?

The DeGregorio Family Foundation is headquartered in Pleasantville, United States, in the North America region.

How does The DeGregorio Family Foundation make money?

One revenue line is on record: donations and Contributions.

Who are The DeGregorio Family Foundation's main competitors?

Direct peers on record are Lustgarten Foundation, Esophageal Cancer Education Foundation (ECEF), SALGI Foundation and No Stomach for Cancer. Broad incumbents are American Cancer Society, V Foundation for Cancer Research, Prevent Cancer Foundation, Damon Runyon Cancer Research Foundation and Cancer Research Institute. Rally Foundation for Childhood Cancers is listed as a regional player.

Does The DeGregorio Family Foundation have an API?

No public API is recorded for The DeGregorio Family Foundation.

What industry is The DeGregorio Family Foundation in?

The DeGregorio Family Foundation's product category is Nonprofit Cancer Research Foundation. Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations, with a secondary code of BPAGAKAI, Research & Science Grantmaking Foundations. Its NAICS code is 813211 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Aijourn$500,000 Michael F. Price Memorial Grant from DeGregorio Family Foundation Awarded for Novel Gastroesophageal Cancer TherapyThe DeGregorio Family Foundation, with support from the Torrey Coast Foundation, awarded $250,000 to Dr. Timothy C. Wang at Columbia University Irving Medical Center to complete a $500,000 grant for developing a novel gastroesophageal cancer therapy called Modified Trefoil Factor Family 2 (TFF2-MSA). The research focuses on a peptide that selectively targets immunosuppressive neutrophils while preserving tumor-inhibitory neutrophils, enabling T cells to better infiltrate and destroy tumors; mouse studies showed significant tumor reduction and better survival with TFF2-MSA. The foundation, founded in 2006 after stomach cancer deaths in the DeGregorio family, aims to advance this therapy toward clinical trials as an alternative for patients facing poor prognoses due to the chemo-resistant nature of gastric and esophageal cancers.PR Newswire$500,000 Michael F. Price Memorial Grant from DeGregorio Family Foundation Awarded for Novel Gastroesophageal Cancer TherapyThe DeGregorio Family Foundation, with support from the Torrey Coast Foundation, awarded $250,000 to Dr. Timothy C. Wang at Columbia University Irving Medical Center to complete his $500,000 grant for developing a novel gastroesophageal cancer therapy called TFF2-MSA. The therapy uses a modified TFF2 peptide to target immunosuppressive neutrophils in tumors, showing significant tumor reduction and improved survival in mouse studies, with potential for combination with existing checkpoint blockade drugs. Dr. Wang's research aims to advance the therapy toward clinical trials for gastric and esophageal cancers, which combined killed over 1.1 million people worldwide in 2022.PR NewswireDeGregorio Family Foundation Marks 20 Years of Advancing Gastric and Esophageal Cancer ResearchThe DeGregorio Family Foundation is celebrating its 20th anniversary as the only public foundation dedicated exclusively to funding research for gastric and esophageal cancers, having awarded nearly $10 million in 38 competitive research grants to leading institutions since its founding in 2006. The Foundation recently awarded its Michael F. Price Memorial Grant in Fall 2025 to studies at Dana-Farber Cancer Institute and The University of Texas MD Anderson Cancer Center, supporting early-stage and clinical trial research. Looking ahead, the Foundation continues its mission to advance research in a historically underfunded field, with plans to focus on high-impact projects closer to patient applications.PR Newswire$500,000 Michael F. Price Grant Awarded to MD Anderson for Gastric Cancer Clinical TrialThe DeGregorio Family Foundation, with support from the Torrey Coast Foundation, awarded a $500,000 Michael F. Price Memorial Grant to The University of Texas MD Anderson Cancer Center for an innovative gastric cancer clinical trial. The trial, led by Dr. Katy Rezvani and Dr. Brian Badgwell, combines surgical tumor removal, direct chemotherapy delivery to the peritoneal cavity, and next-generation engineered NK cell immunotherapy targeting stage IV gastric cancer with peritoneal metastases. The research team will also study tissue samples to identify new therapeutic targets and patient populations most likely to benefit from this approach.PR Newswire$750,000 Michael F. Price Grant Awarded to Move Novel Cellular Therapy for Gastroesophageal Cancer into the ClinicThe DeGregorio Family Foundation, with support from Torrey Coast Foundation, awarded a $750,000 Michael F. Price Memorial Grant to Dr. Eric Smith and Dr. Andrew Aguirre of Dana-Farber Cancer Institute and Dr. Sam Klempner of Massachusetts General Hospital for clinical translation of a novel dual-targeted CAR T cell therapy for advanced gastroesophageal cancer. The therapy uses an "OR-gated" dual-CAR design targeting two tumor markers to overcome tumor heterogeneity and plasticity, with preclinical studies demonstrating elimination of GEA tumors; the team is entering final preclinical stages for a first-in-human Phase I trial. The funding addresses a critical translational research gap, as gastric and esophageal cancers combined killed over 1.3 million people worldwide in 2020 and patients continue to face poor prognoses due to chemo-resistant behavior.PR NewswireMichael F. Price Memorial Grant Supports Breakthrough in Cancer Stem Cell Research - Providing Groundwork for Phase I Clinical TrialThe DeGregorio Family Foundation, with support from the Esophageal Cancer Awareness Association, has awarded a $75,000 Michael F. Price Memorial Grant to Dr. Anthony Capobianco at the University of Miami Miller School of Medicine to advance cancer stem cell research toward a Phase I clinical trial. The funding will support preclinical work on two novel drugs (SSTN-302 and SST-1034) that simultaneously target the Notch and Wnt pathways to eliminate cancer stem cells in patients with advanced esophageal and gastrointestinal cancers. The research, conducted in collaboration with StemSynergy Therapeutics, aims to address the poor prognoses of these cancers, which were responsible for more than 1.3 million deaths worldwide in 2020.PR Newswire$500,000 Awarded to Identify and Exploit New Druggable Targets in Gastroesophageal CancerThe DeGregorio Family Foundation, with support from the Torrey Coast Foundation, awarded $300,000 to Dr. Eric S. Fischer at Dana-Farber Cancer Institute to complete a $500,000 grant for gastroesophageal cancer research focused on targeted protein degradation therapeutics. The research aims to develop "degrader" molecules that can remove disease-causing proteins, addressing a critical gap in treatment options for these lethal cancers that killed over 1.3 million people worldwide in 2020. The foundation, founded in 2006 after losing family members to stomach cancer, has raised more than $8 million to fund research into gastric and esophageal cancers.PR NewswireMichael F. Price Memorial Grant from DeGregorio Family Foundation Awarded for Progress in Research to Disrupt Cancer Stem CellsThe DeGregorio Family Foundation, with support from the Esophageal Cancer Awareness Association, awarded a $100,000 grant to Dr. Anthony Capobianco at the University of Miami Miller School of Medicine for research targeting cancer stem cells in upper GI cancers through dual inhibition of Notch and Wnt pathways.PR NewswireMichael F. Price Memorial Grant from the DeGregorio Family Foundation Awarded for Esophageal Cancer ResearchThe DeGregorio Family Foundation, with support from the Esophageal Cancer Awareness Association, awarded a $75,000 grant named in memory of Michael F. Price to Dr. R. Taylor Ripley and Dr. Yuan Xu at Baylor College of Medicine for esophageal cancer research. The researchers are investigating whether targeting a mitochondrial protein called Mcl-1 can overcome treatment resistance in esophageal adenocarcinoma, building on $75,000 awarded in 2023 with potential for additional funding based on results. The foundation, founded in 2006, has raised over $8 million to fund research for gastric and esophageal cancers, which combined killed over 1.3 million people worldwide in 2020.PR NewswireAdvances Made in Grant to Improve Immunotherapy in Gastroesophageal CancerThe DeGregorio Family Foundation, with support from the Torrey Coast Foundation, awarded $300,000 to researchers at Dana-Farber Cancer Institute and Massachusetts General Hospital to advance immunotherapy research in gastroesophageal cancer, building on $250,000 previously awarded in November 2022. The research team is developing a dual-targeted CAR T cell therapy using patient tumor samples to target two cell surface antigens, with the goal of achieving more durable responses than current single-antigen approaches. The grant funding could increase up to $1 million depending on research results.